Skip to main content
Premium Trial:

Request an Annual Quote

Avaki Data Grid, Oracle, EMC, InterPro 7.0

Premium

Avaki will launch version 4.0 of the Avaki Data Grid on July 29. The latest version of the company’s data grid software provides an integration layer based on XML and XSLT (extensible stylesheet transformation). The company is offering a “quick connect” pilot package for $35,000. Philip Werner, VP of product management at Avaki, said that three customers are currently beta-testing Data Grid 4.0.

 

Oracle has released its 11i.9 E-Business Suite, with several enhancements designed to meet the needs of the life science industry, including new capabilities to manage electronic signatures and secure audit trails for compliance with the FDA’s 21 CFR Part 11 regulatory requirement. Additional features include support for validation procedures, production batch record management, and a process quality workbench to integrate quality into all aspects of production.

 

EMC has launched an automated billing program for its line of storage infrastructure products. The program, called OpenScale, lets customers allocate additional storage resources on demand, but be billed only for the resources used. OpenScale automated billing is available for the company’s Symmetrix, Clariion, Connectrix, and Celerra storage systems.

 

InterPro 7.0 is available from the European Bioinformatics Institute at http://www.ebi.ac.uk/interpro/. The database, an integrated resource combining protein families, domains, and functional sites from Swiss-Prot, Trembl, Prosite, Prints, Pfam, and ProDom, now includes information from the Superfamily hidden Markov model database. InterPro 7.0 contains 8,547 entries, representing 1,902 domains, 6,416 families, 163 repeats, 26 active sites, 20 binding sites and 20 post-translational modifications.

Filed under

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.